Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to her Department's consultation on Expanding access to naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions her Department has had with NHS England and Barts Health NHS Trust on the ongoing dispute.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Department officials have held discussions with NHS England regarding the strike action held at Barts Health NHS Trust. However, this is a local dispute that should be managed locally by the trust, so no direct discussions have been held with Barts Health NHS Trust on this matter.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the (a) physical and (b) mental ability of NHS staff to work beyond the state pension age.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
No recent assessment has been made. National Health Service staff are not expected to work beyond state pension age, though some choose to do so. The NHS Pension Scheme is generous, and provides good pensions for retirement. The scheme offers a partial retirement option, which allows staff to draw down part of their pension and continue working in a more flexible way.
The NHS Long Term Workforce Plan commits to going beyond statutory requirements in supporting and promoting flexible working opportunities. NHS England have produced guidance for employers on supporting their older workforce, together with a wide-ranging package of support for NHS staff. This includes tools and resources to support line managers to hold meaningful conversations with staff to discuss their well-being, and emotional and psychological health and wellbeing support.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will increase the pay of junior doctors; and when she next plans to meet their representatives to discuss pay.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Junior Doctors have already received a pay uplift of up to 10.3% for 2023-2024.
When industrial action is called, the Government’s priority is supporting the National Health Service to prepare for that action and keep patients safe. On that basis, my right hon. Friend will not meet with the British Medical Association Junior Doctors Committee when strike action has been called.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle sexual abuse of female paramedics.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England commissioned a review into the ambulance sector culture and has welcomed the recommendations of the recent independent review, which highlights the need to target bullying and harassment, including sexual harassment, and enable the freedom to speak up.
NHS England are setting up a Delivery Board alongside an implementation plan to deliver the recommendations from the Ambulance Sector Culture report. This will include actions related to stopping misogyny and improving sexual safety in the ambulance service by the Office of the Chief Allied Health Professions at NHS England and the Association of Ambulance Chief Executives.
Last year, NHS England launched the first-ever sexual safety charter in collaboration with healthcare systems, to provide staff with clear reporting mechanisms, training, and support, ensuring that a zero-tolerance approach to tackle sexual misconduct is taken.
The 2023 NHS Staff Survey included a new question specifically around unwanted behaviour of a sexual nature to enable National Health Service organisations to understand the prevalence of misconduct in their workplace, which will inform further action to protect and support staff across the NHS. The results of the 2023 NHS Staff Survey will be published on 7 March 2024.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to her Oral Statement of 7 February 2024 on NHS Dentistry: Recovery and Reform, Official Report, columns 251-253, whether she has made an estimate of the impact of the announcement to offer additional payments for check-ups and new patients on the number of new dental surgeries that will be established in each of the next five years.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Dentistry Recovery Plan will make dental services faster, simpler, and fairer for patients and will fund approximately two and a half million additional appointments, or more than one and a half million additional courses of dental treatment. As part of the plan, we will launch a new Golden Hello scheme for dentists who want to move to areas which persistently struggle to attract dentists into National Health Service work. The scheme will provide an extra two and a half million appointments, with 20,000 to be offered per dentist, for up to 240 dentists over three years.
We recognise that some commissioners will also be looking to commission new dentistry capacity to support under-served areas. We will support integrated care boards to ensure they understand how commissioning teams can encourage development of their local provider market, and to identify what further support they may need to develop new capacity, where they would otherwise be dependent on existing contractors and facilities to deliver improvements in access.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the impact of administering naloxone when (a) reversing an overdose and (b) no opioids are present in the system.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government considers naloxone to be effective in reducing opioid overdose-related deaths and is working to widen access to, and increase the uptake of, this life saving drug. The Naloxone consultation published on 24 January 2024 seeks views on proposals to expand access to take-home naloxone supplies, with more information available at the following link:
Naloxone has a very good safety profile. Using medicines is never without risk but the government’s assessment and the clinical consensus is that the benefits of naloxone far outweigh the risks. Naloxone remains effective when used to reverse the effects of an overdose caused by synthetic opioids.
Naloxone's safety means it is highly unlikely to harm someone if it is administered to them and they are not overdosing on an opioid.